PT97888A - Processo para a preparacao de compostos heterociclicos derivados de indol e de composicoes farmaceuticas que os contem - Google Patents

Processo para a preparacao de compostos heterociclicos derivados de indol e de composicoes farmaceuticas que os contem

Info

Publication number
PT97888A
PT97888A PT97888A PT9788891A PT97888A PT 97888 A PT97888 A PT 97888A PT 97888 A PT97888 A PT 97888A PT 9788891 A PT9788891 A PT 9788891A PT 97888 A PT97888 A PT 97888A
Authority
PT
Portugal
Prior art keywords
indol
preparation
pharmaceutical compositions
compositions containing
heterocyclic compounds
Prior art date
Application number
PT97888A
Other languages
English (en)
Other versions
PT97888B (pt
Inventor
Alan Duncan Robertson
Alan Peter Hill
Robert Charles Glen
Graeme Richard Martin
Original Assignee
Wellcome Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26297174&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT97888(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB909012672A external-priority patent/GB9012672D0/en
Priority claimed from GB919102182A external-priority patent/GB9102182D0/en
Application filed by Wellcome Found filed Critical Wellcome Found
Publication of PT97888A publication Critical patent/PT97888A/pt
Publication of PT97888B publication Critical patent/PT97888B/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Steroid Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Cephalosporin Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
PT97888A 1990-06-07 1991-06-06 Processo para a preparacao de compostos heterociclicos derivados de indol e de composicoes farmaceuticas que os contem PT97888B (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB909012672A GB9012672D0 (en) 1990-06-07 1990-06-07 Therapeutic heterocyclic compounds
GB919102182A GB9102182D0 (en) 1991-02-01 1991-02-01 Therapeutic heterocyclic compounds

Publications (2)

Publication Number Publication Date
PT97888A true PT97888A (pt) 1992-05-29
PT97888B PT97888B (pt) 1998-12-31

Family

ID=26297174

Family Applications (1)

Application Number Title Priority Date Filing Date
PT97888A PT97888B (pt) 1990-06-07 1991-06-06 Processo para a preparacao de compostos heterociclicos derivados de indol e de composicoes farmaceuticas que os contem

Country Status (37)

Country Link
US (3) US5399574A (pt)
EP (2) EP0486666B1 (pt)
JP (1) JP2738461B2 (pt)
KR (1) KR100215627B1 (pt)
AT (2) ATE204275T1 (pt)
AU (1) AU646871B2 (pt)
CA (2) CA2064815C (pt)
CZ (1) CZ288351B6 (pt)
DE (3) DE69127260T2 (pt)
DK (1) DK0486666T3 (pt)
EG (1) EG19650A (pt)
ES (1) ES2104708T3 (pt)
FI (3) FI105686B (pt)
GR (1) GR3024828T3 (pt)
HK (1) HK1000534A1 (pt)
HR (1) HRP940524B1 (pt)
HU (2) HU219974B (pt)
IE (1) IE911931A1 (pt)
IL (3) IL114690A (pt)
LT (1) LT3264B (pt)
LU (1) LU90205I2 (pt)
LV (1) LV10274B (pt)
MC (1) MC2210A1 (pt)
MX (1) MX9203421A (pt)
MY (1) MY110226A (pt)
NL (1) NL980001I2 (pt)
NO (2) NO300634B1 (pt)
NZ (1) NZ238424A (pt)
PL (1) PL166214B1 (pt)
PT (1) PT97888B (pt)
RU (1) RU2160736C2 (pt)
SA (1) SA05260104B1 (pt)
SI (2) SI21560B (pt)
SK (1) SK281621B6 (pt)
UA (1) UA37178C2 (pt)
WO (1) WO1991018897A1 (pt)
YU (1) YU48855B (pt)

Families Citing this family (122)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ283018B6 (cs) * 1991-02-01 1997-12-17 Merck Sharp And Dohme Limited Deriváty imidazolu, triazolu a tetrazolu a farmaceutické přípravky na jejich bázi
TW263508B (pt) * 1991-02-12 1995-11-21 Pfizer
BR9206810A (pt) * 1991-11-25 1995-10-31 Pfizer Derivados de indol
GB9201038D0 (en) * 1992-01-16 1992-03-11 Glaxo Group Ltd Chemical compounds
TW288010B (pt) * 1992-03-05 1996-10-11 Pfizer
WO1993018029A1 (en) * 1992-03-13 1993-09-16 Merck Sharp & Dohme Limited Imidazole, triazole and tetrazole derivatives
GB9207396D0 (en) * 1992-04-03 1992-05-13 Merck Sharp & Dohme Therapeutic agents
US5747501A (en) 1992-04-07 1998-05-05 Pfizer, Inc. Indole derivatives
US6380233B1 (en) 1992-04-07 2002-04-30 Pfizer Inc Indole derivatives as 5-HT1 agonists
AU670270B2 (en) * 1992-04-10 1996-07-11 Pfizer Inc. Acylaminoindole derivatives as 5-HT1 agonists
GB9207930D0 (en) * 1992-04-10 1992-05-27 Pfizer Ltd Indoles
GB9208161D0 (en) * 1992-04-14 1992-05-27 Pfizer Ltd Indoles
GB9208463D0 (en) * 1992-04-16 1992-06-03 Merck Sharp & Dohme Therapeutic agents
GB9209882D0 (en) * 1992-05-07 1992-06-24 Glaxo Lab Sa Compositions
GB9211277D0 (en) 1992-05-28 1992-07-15 Glaxo Group Inc Pharmaceutical compositions
CA2138649A1 (en) * 1992-07-24 1994-02-03 Raymond Baker Imidazole, triazole and tetrazole derivatives
GB9216009D0 (en) * 1992-07-28 1992-09-09 Almirall Lab New indol derivatives
IL106445A (en) * 1992-07-30 1998-01-04 Merck Sharp & Dohme History of 1,2,4-Trans-Triazole 4-Transform, Preparation and Pharmaceutical Preparations Containing Them
ES2056025B1 (es) * 1992-10-08 1995-05-01 Almirall Lab Nuevos derivados de indol.
TW251284B (pt) * 1992-11-02 1995-07-11 Pfizer
GB9226532D0 (en) * 1992-12-21 1993-02-17 Smithkline Beecham Plc Compounds
FR2701026B1 (fr) * 1993-02-02 1995-03-31 Adir Nouveaux dérivés de l'indole, de l'indazole et du benzisoxazole, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent.
ES2070087B1 (es) * 1993-08-13 1996-02-16 Pfizer Derivados de indol
DK0716649T3 (da) * 1993-08-31 1999-02-08 Pfizer 5-Arylindolderivater
US6423731B2 (en) * 1994-01-06 2002-07-23 Zeneca Limited Indole derivatives as prodrugs of 5-HT1-like receptor agonists
US5468768A (en) * 1994-01-06 1995-11-21 Bristol-Myers Squibb Company Antimigraine derivatives of indolylcycloalkanylamines
US5962486A (en) * 1994-06-01 1999-10-05 Zeneca Limited Indole derivatives as prodrugs of 5-HT1 -like receptor agonists
GB9401436D0 (en) * 1994-01-26 1994-03-23 Wellcome Found Therapeutic heterocyclic compounds
EP0759918A1 (en) * 1994-05-19 1997-03-05 MERCK SHARP & DOHME LTD. Piperazine, piperidine and tetrahydropyridine derivatives of indol-3-ylalkyl as 5-ht1d-alpha agonists
CA2194984C (en) * 1994-07-26 2002-07-02 John Eugene Macor 4-indole derivatives as serotonin agonists and antagonists
US5521196A (en) * 1994-10-05 1996-05-28 Eli Lilly And Company 5-HT1F agonists for the treatment of migraine
GB9423682D0 (en) * 1994-11-23 1995-01-11 Merck Sharp & Dohme Therapeutic agents
US5521197A (en) * 1994-12-01 1996-05-28 Eli Lilly And Company 3-<1-alkylenearyl>-4-<1,2,3,6-tetrahydropyridinyl>-and 3-<1-alkylenearyl>-4-piperidinyl-1h-indoles: new 5-HT1F agonists
CA2207201A1 (en) * 1994-12-06 1996-06-13 Caroline Henry Azetidine, pyrrolidine and piperidine derivatives as 5ht1 receptor agonists
DE4443892A1 (de) * 1994-12-09 1996-06-13 Bayer Ag 4-(Chinolin-2-yl-methoxy)-phenyl-essigsäurederivate
GB9501865D0 (en) * 1995-01-31 1995-03-22 Merck Sharp & Dohme Therapeutic agents
KR19980703048A (ko) * 1995-03-20 1998-09-05 피터쥐.스트링거 5-치환-3-(1,2,3,6-테트라히드로피리딘-4-일)- 및 3-(피페리딘-4-일)-1ｈ-인돌: 신규한 5-ｈｔ1ｆ 아고니스트
GB9515060D0 (en) * 1995-07-22 1995-09-20 Wellcome Found Therapeutic heterocyclic compounds
GB9515305D0 (en) * 1995-07-26 1995-09-20 Wellcome Found Therapeutic heterocyclic compounds
GB9516145D0 (en) * 1995-08-07 1995-10-04 Wellcome Found Improved chemical synthesis
GB9516143D0 (en) 1995-08-07 1995-10-04 Wellcome Found Improved chemical synthesis
US6909005B1 (en) * 1995-08-07 2005-06-21 Astrazeneca Uk Limited One post synthesis of 2-oxazolidinone derivatives
WO1997013512A1 (en) * 1995-10-10 1997-04-17 Eli Lilly And Company N-[2-substituted-3-(2-aminoethyl)-1h-indol-5-yl]-amides: new 5-ht1f agonists
US5998415A (en) * 1995-11-02 1999-12-07 Merck Sharp & Dohme Ltd. Bicyclic heteroaryl-alkylene-(homo)piperazinones and thione analogues thereof, their preparation, and their use of as selective agonists of 5-HT1 -like receptors
GB9609374D0 (en) * 1996-05-03 1996-07-10 Merck Sharp & Dohme Therapeutic agents
US5891885A (en) * 1996-10-09 1999-04-06 Algos Pharmaceutical Corporation Method for treating migraine
GB9706089D0 (en) 1997-03-24 1997-05-14 Scherer Ltd R P Pharmaceutical composition
US6066092A (en) * 1997-11-06 2000-05-23 Cady; Roger K. Preemptive prophylaxis of migraine device and method
US7189753B1 (en) 1997-11-06 2007-03-13 Cady Roger K Preemptive prophylaxis of migraine
AR017200A1 (es) 1997-12-23 2001-08-22 Astrazeneca Ab Compuestos inhibidores de la proteina cinasa c, sales farmaceuticamente aceptables de los mismos, formulaciones farmaceuitcas que los comprenden, usode las mismas y proceso para la sintesis de dichos compuestos
SE9800835D0 (sv) 1998-03-13 1998-03-13 Astra Ab New Compounds
WO2000000490A2 (en) * 1998-06-26 2000-01-06 Eli Lilly And Company 5-ht1f agonists
US6492406B1 (en) 1999-05-21 2002-12-10 Astrazeneca Ab Pharmaceutically active compounds
US6346625B1 (en) * 1999-06-23 2002-02-12 Astrazeneca Ab Protein kinase inhibitors
GB9928578D0 (en) * 1999-12-03 2000-02-02 Zeneca Ltd Pharmaceutical formulations
JP2004517081A (ja) * 2000-11-29 2004-06-10 イーライ・リリー・アンド・カンパニー １−（２−ｍ−メタンスルホンアミドフェニルエチル）−４−（ｍ−トリフルオロメチルフェニル）ピペラジンならびにその医薬的に許容しうる塩および溶媒和物
US7090830B2 (en) * 2001-05-24 2006-08-15 Alexza Pharmaceuticals, Inc. Drug condensation aerosols and kits
US7458374B2 (en) * 2002-05-13 2008-12-02 Alexza Pharmaceuticals, Inc. Method and apparatus for vaporizing a compound
US7645442B2 (en) 2001-05-24 2010-01-12 Alexza Pharmaceuticals, Inc. Rapid-heating drug delivery article and method of use
US7766013B2 (en) * 2001-06-05 2010-08-03 Alexza Pharmaceuticals, Inc. Aerosol generating method and device
US20070122353A1 (en) 2001-05-24 2007-05-31 Hale Ron L Drug condensation aerosols and kits
US8329734B2 (en) 2009-07-27 2012-12-11 Afgin Pharma Llc Topical therapy for migraine
DK1435945T3 (da) * 2001-06-05 2008-12-01 Ronald Aung-Din Topisk migræne terapi
US6685951B2 (en) 2001-07-05 2004-02-03 R. T. Alamo Ventures I, Inc. Administration of dihydroergotamine as a sublingual spray or aerosol for the treatment of migraine
US20030017175A1 (en) * 2001-07-05 2003-01-23 R.T. Alamo Ventures I, Inc. Sublingual administration of dihydroergotamine for the treatment of migraine
US20030198669A1 (en) * 2001-07-05 2003-10-23 R.T. Alamo Ventures I, Llc Compositions and methods for rapid dissolving formulations of dihydroergotamine and caffeine for the treatment of migraine
EP2266590A3 (en) 2002-02-22 2011-04-20 Shire LLC Active agent delivery sytems and methods for protecting and administering active agents
WO2004000845A1 (en) 2002-06-21 2003-12-31 Suven Life Sciences Limited Arylalkyl indoles having sertonin receptor affinity useful as therapeutic agents, process for their preparation and pharmaceutical compositions containing them
ES2297216T3 (es) 2002-06-21 2008-05-01 Suven Life Sciences Limited Indoles tetraciclicos arilsulfonil que tienen afinidad con el receptor de la serotonina.
ES2204302B2 (es) 2002-08-07 2005-03-01 Laboratorios Vita, S.A. Procedimiento para la obtencion de un compuesto farmaceuticamente activo.
US20040105818A1 (en) * 2002-11-26 2004-06-03 Alexza Molecular Delivery Corporation Diuretic aerosols and methods of making and using them
US7913688B2 (en) * 2002-11-27 2011-03-29 Alexza Pharmaceuticals, Inc. Inhalation device for producing a drug aerosol
SI1567492T1 (sl) 2002-11-28 2013-07-31 Suven Life Sciences Limited N-arilsulfonil-3-aminoalkoksiindoli
ATE401307T1 (de) 2002-11-28 2008-08-15 Suven Life Sciences Ltd N-arylsulfonyl-2-substituierte indole mit affinität zum serotonin rezeptor, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzungen
DK1581538T3 (da) 2002-12-18 2007-06-25 Suven Life Sciences Ltd Tetracykliske 3-substituerede indoler med serotoninreceptoraffinitet
CA2508290C (en) 2002-12-20 2017-02-28 Ciba Specialty Chemicals Holding Inc. Synthesis of amines and intermediates for the synthesis thereof
WO2004063175A1 (en) * 2003-01-13 2004-07-29 Natco Pharma Limited A novel and an improved process for the preparation of (s)-4-(4-aminobenzyl)-2- oxazolidinone
GB0302094D0 (en) 2003-01-29 2003-02-26 Pharmagene Lab Ltd EP4 receptor antagonists
US20040192958A1 (en) * 2003-03-25 2004-09-30 Hyatt John Anthony Process for preparing derivatives of 4-halobutyraldehyde
EP1625334B9 (en) 2003-05-21 2012-07-25 Alexza Pharmaceuticals, Inc. Percussively ignited self-contained heating unit
MY142655A (en) * 2003-06-12 2010-12-15 Euro Celtique Sa Therapeutic agents useful for treating pain
WO2004112723A2 (en) * 2003-06-20 2004-12-29 Ronald Aung-Din Tropical therapy for the treatment of migraines, muscle sprains, muscle spasm, spasticity and related conditions
EP1648878B9 (en) * 2003-07-24 2011-03-16 Euro-Celtique S.A. Piperidine compounds and pharmaceutical compositions containing them
GB0324269D0 (en) 2003-10-16 2003-11-19 Pharmagene Lab Ltd EP4 receptor antagonists
WO2005075467A2 (en) * 2004-02-06 2005-08-18 Ciba Specialty Chemicals Holding Inc. Crystalline forms of zolmitriptan
US7540286B2 (en) * 2004-06-03 2009-06-02 Alexza Pharmaceuticals, Inc. Multiple dose condensation aerosol devices and methods of forming condensation aerosols
AU2004322756B2 (en) * 2004-08-12 2011-04-14 Alexza Pharmaceuticals, Inc. Aerosol drug delivery device incorporating percussively activated heat packages
EP1812428A2 (en) * 2004-11-19 2007-08-01 Teva Pharmaceutical Industries Ltd Zolmitriptan crystal forms
PL1883451T3 (pl) 2005-04-13 2011-05-31 Neuraxon Inc Podstawione związki indolowe mające aktywność hamowania NOS
EP1981860B1 (en) 2006-01-19 2011-05-25 Matrix Laboratories Ltd Conversion of aromatic diazonium salt to aryl hydrazine
AR060451A1 (es) * 2006-04-13 2008-06-18 Neuraxon Inc Compuestos de indol 1,5 y 3,6-sustituidos con actividad inhibitoria de nos
WO2008018090A2 (en) * 2006-08-09 2008-02-14 Matrix Laboratories Ltd An improved process for the preparation of zolmitriptan
AU2007310949A1 (en) * 2006-10-19 2008-04-24 Auspex Pharmaceuticals, Inc. Substituted indoles
EP2425820B1 (en) 2007-02-11 2015-04-08 MAP Pharmaceuticals Inc Method of therapeutic administration of dhe to enable rapid relief of migraine while minimizing side effect profile
CZ2007158A3 (cs) * 2007-02-26 2008-10-22 Zentiva, A. S. Zpusob prípravy zolmitriptanu
ES2594867T3 (es) 2007-03-09 2016-12-23 Alexza Pharmaceuticals, Inc. Unidad de calentamiento para usar en un dispositivo de administración de fármaco
EP2479173A1 (en) * 2007-04-27 2012-07-25 Purdue Pharma LP Therapeutic agents useful for treating pain
MX2009011600A (es) 2007-04-27 2010-11-26 Purdue Pharma Lp Antagonistas de trpvi y usos de los mismos.
CN101883766A (zh) * 2007-10-03 2010-11-10 基因里克斯(英国)有限公司 制备佐米曲普坦、其盐和溶剂化物的方法
CA2705422A1 (en) * 2007-11-16 2009-05-22 The Arizona Board Of Regents On Behalf Of The University Of Arizona Methods for treating visceral pain
CN101910157B (zh) 2007-11-16 2014-05-07 纽尔亚商股份有限公司 吲哚化合物和治疗内脏痛的方法
US20090131503A1 (en) * 2007-11-16 2009-05-21 Annedi Subhash C 3,5 - substituted indole compounds having nos and norepinephrine reuptake inhibitory activity
CN101181267B (zh) * 2007-11-30 2010-09-08 重庆医科大学医药研究所 佐米曲普坦舌下片
KR101517415B1 (ko) * 2008-05-14 2015-05-07 에스케이바이오팜 주식회사 난용성 항경련제를 함유하는 경비 항경련성 약학 조성물
AU2009269129B2 (en) 2008-06-30 2015-08-20 Afgin Pharma, Llc Topical regional neuro-affective therapy
US20100217013A1 (en) * 2008-12-15 2010-08-26 Wenge Li Enantioselective process for the preparation of zolmitriptan
US20110171141A1 (en) * 2009-06-26 2011-07-14 Kellerman Donald J Administration of dihydroergotamine mesylate particles using a metered dose inhaler
US20110038928A1 (en) * 2009-08-12 2011-02-17 Glenmark Generics Ltd Orally disintegrating tablets of zolmitriptan
LT2627328T (lt) 2010-10-15 2016-11-25 Contera Pharma Aps Serotonino receptorių agonistų deriniai, skirti judėjimo sutrikimų gydymui
SI2723732T1 (sl) 2011-06-22 2017-05-31 Purdue Pharma Lp One Stamford Forum Antagonisti trpv1, vključno z dihidroksi substituentom, in njihova uporaba
PL2734634T3 (pl) 2011-07-22 2020-03-31 The University Of Chicago Igf-1 do zastosowania do leczenia migreny
US9006453B2 (en) 2011-09-02 2015-04-14 Emcure Pharmaceuticals Limited Process for preparation of zolmitriptan
EP2838517B1 (en) 2012-04-18 2017-10-18 Contera Pharma APS Orally available pharmaceutical formulation suitable for improved management of movement disorders
WO2014100351A2 (en) 2012-12-21 2014-06-26 Map Pharmaceuticals, Inc. 8'-hydroxy-dihydroergotamine compounds and compositions
US10383816B2 (en) 2015-03-02 2019-08-20 Afgin Pharma, Llc Topical regional neuro-affective therapy with cannabinoid combination products
CN107530318A (zh) 2015-03-02 2018-01-02 阿福金制药有限责任公司 用大麻素的局部区域神经影响性疗法
WO2017122161A1 (en) 2016-01-15 2017-07-20 Cadila Healthcare Limited An intranasal composition comprising 5ht1b/1d receptor agonists
CN108697637A (zh) 2016-01-27 2018-10-23 因斯塔尔科技股份公司 用于治疗性处理的口腔粘膜纳米纤维载体
JP7227896B2 (ja) 2016-07-11 2023-02-22 コンテラ ファーマ エー／エス 朝の無動状態を治療するための拍動性薬物送達系
US20180049994A1 (en) 2016-08-16 2018-02-22 Afgin Pharma, Llc Topical regional neuro-affective therapy with caryophyllene
EP3766483A1 (en) 2019-07-19 2021-01-20 BioPharma Synergies, S. L. Orodispersible powder composition comprising a triptan
US20210322343A1 (en) 2020-04-15 2021-10-21 Farzana Shaheen Nasally administered pharmaceutical composition for the treatment of epilepsy and related disorders

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB148879A (en) * 1919-02-14 1921-11-10 Emil Vincance Noser Locks for shift levers of automobiles
US3320282A (en) * 1962-10-29 1967-05-16 Pfizer & Co C Process for preparing esters of 2-hydroxy-3-(3-indolyl) alkanoic acids
US3879410A (en) * 1971-02-08 1975-04-22 Messrs Lab Guidotti & C S P A 4-Aryl-4-oxazolin-2-ones exhibiting myotonic and myorelaxing activity
BE795457A (fr) * 1972-02-16 1973-08-16 Clin Midy Amines indoliques, leur preparation et leur application en therapeutiques
FR2179582B1 (pt) * 1972-04-13 1975-10-10 Synthelabo
US3873559A (en) * 1973-03-30 1975-03-25 Squibb & Sons Inc Heterocyclic carboxamido thiazolinyl indoles
US4042595A (en) * 1973-08-01 1977-08-16 Snam Progetti S.P.A. Processes for the production of heterocyclic compounds
IT995110B (it) * 1973-08-01 1975-11-10 Snam Progetti Procedimento per la produzione di composti eterociclici e prodotti ottenuti
US3931229A (en) * 1973-08-23 1976-01-06 Warner-Lambert Company 3-Thiomethyl-2[2-(dialkylamino)ethyl]indoles
US4049816A (en) * 1975-03-24 1977-09-20 Beecham Group Limited Antiviral 2-amino-5-[1-(indol-3-yl)alkyl]-2-thiazolin-4-ones
US4062862A (en) * 1975-07-04 1977-12-13 Nippon Chemiphar Co., Ltd. 5-Benzyl-2-oxazolidone derivatives and a process for producing the same
GB1482879A (en) * 1975-07-24 1977-08-17 Nippon Chemiphar Co 5-benzyl-2-oxazolidone derivatives and a process for producing the same
GB1469200A (en) * 1975-11-28 1977-03-30 Warner Lambert Co 3-thiomethyl-2-2-dialkylamino-ethyl-indoles
DE2557341A1 (de) * 1975-12-19 1977-06-30 Hoechst Ag Basisch substituierte indolderivate und verfahren zu ihrer herstellung
IT1109002B (it) * 1977-09-22 1985-12-16 Menarini Sas Derivati del 2 oxazolidone e loro metodi di preparazione
US4137404A (en) * 1977-12-20 1979-01-30 Hoffmann-La Roche Inc. Synthesis of tryptophans
US4198501A (en) * 1977-12-20 1980-04-15 Hoffmann-La Roche Inc. Synthesis of tryptophans
JPS6014032B2 (ja) * 1978-01-20 1985-04-11 日本ケミフア株式会社東京 ５‐フエネチル‐２‐オキサゾリドン誘導体およびその製法
US4348393A (en) * 1978-06-09 1982-09-07 Delalande S.A. N-Aryl oxazolidinones, oxazolidinethiones, pyrrolidinones, pyrrolidines and thiazolidinones
DE2933636A1 (de) * 1978-08-30 1980-03-20 Sandoz Ag Neue n-phenylindolinderivate, ihre herstellung und pharmazeutische praeparate, welche diese verbindungen enthalten
ZA795239B (en) * 1978-10-12 1980-11-26 Glaxo Group Ltd Heterocyclic compounds
US4255432A (en) * 1979-09-06 1981-03-10 Syntex (U.S.A.) Inc. 8-[2-3-Indolyl)ethyl]-1-oxa-3-,8-diazaspiro[4.5]decan-2-ones, pharmaceutical compositions thereof and methods of use thereof
US4272555A (en) * 1979-09-21 1981-06-09 Monsanto Company Conversion of carbon-containing materials to carbon monoxide
EP0038298B1 (en) * 1980-04-10 1984-07-25 Sandoz Ag Isoxazolyl indolamines
JPS574986A (en) * 1980-06-13 1982-01-11 Paamakemu Asia:Kk Preparation of oxazolidine derivative
US4753956A (en) * 1981-01-02 1988-06-28 Pfizer Inc. Hypoglycemic 5-substituted oxazolidine-2,4-diones
US4367234A (en) * 1980-07-28 1983-01-04 Pfizer Inc. Hypoglycemic 5-substituted oxazolidine-2,4-diones
ZW19381A1 (en) * 1980-08-12 1983-03-09 Glaxo Group Ltd Heterocyclic compounds
AU548467B2 (en) * 1980-08-12 1985-12-12 Glaxo Group Limited Tryptamines and their isoindolylethyl derivatives
ZA815541B (en) * 1980-08-12 1983-03-30 Glaxo Group Ltd Heterocyclic compounds
US4399296A (en) * 1981-01-02 1983-08-16 Pfizer Inc. Hypoglycemic 5-substituted oxazolidine-2,4-diones
US4407811A (en) * 1981-01-02 1983-10-04 Pfizer Inc. Hypoglycemic 5-substituted oxazolidine-2,4-diones
US4448971A (en) * 1981-01-02 1984-05-15 Pfizer Inc. Hypoglycemic 5-phenyl-substituted oxazolidine-2,4-diones
JPS57169458A (en) * 1981-04-13 1982-10-19 Paamakemu Asia:Kk Preparation of indole derivative
CH656124A5 (de) * 1982-04-13 1986-06-13 Sandoz Ag 2-substituierte-3-indolamine, verfahren zu deren herstellung sowie deren verwendung.
GR79215B (pt) * 1982-06-07 1984-10-22 Glaxo Group Ltd
US4803218A (en) * 1982-09-29 1989-02-07 Mcneilab, Inc. 3-aminoalkyl-1H-indole-5-urea and amide derivatives
US4500717A (en) * 1983-03-28 1985-02-19 The Dow Chemical Company Process for preparation of 2-oxazolidinones
US4831153A (en) * 1983-06-27 1989-05-16 The Dow Chemical Company Preparation of N-vinyl-2-oxazolidinone
GB8321813D0 (en) * 1983-08-12 1983-09-14 Vickers Plc Radiation sensitive compounds
DE3333450A1 (de) * 1983-09-16 1985-04-11 Hoechst Ag, 6230 Frankfurt Trihalogenmethylgruppen enthaltende carbonylmethylenheterocyclen, verfahren zu ihrer herstellung und lichtempfindliches gemisch, das diese verbindungen enthaelt
HU196752B (en) * 1983-12-06 1989-01-30 Glaxo Group Ltd Process for production of medical compositions containing indole-derivatives and these compounds
DE3430284A1 (de) * 1984-08-17 1986-02-27 Troponwerke GmbH & Co KG, 5000 Köln Neue tryptamin-derivate, ein verfahren zu ihrer herstellung und ihre verwendung
SE8505715L (sv) * 1984-12-04 1986-06-05 Glaxo Group Ltd Indolderivat
GB8431426D0 (en) * 1984-12-13 1985-01-23 Glaxo Group Ltd Chemical compounds
DE3514696A1 (de) * 1985-04-24 1986-11-06 Bayer Ag, 5090 Leverkusen N-indolylethyl-sulfonsaeureamide, verfahren zu ihrer herstellung und ihre verwendung
DE3531658A1 (de) * 1985-09-05 1987-03-12 Boehringer Mannheim Gmbh Heterocyclisch substituierte indole, zwischenprodukte, verfahren zu ihrer herstellung und arzneimittel
DE3678805D1 (de) * 1985-11-08 1991-05-23 Glaxo Group Ltd Indolderivate.
GB8531612D0 (en) * 1985-12-23 1986-02-05 Beecham Wuelfing Gmbh & Co Kg Compounds
SE451840B (sv) * 1986-01-03 1987-11-02 Astra Laekemedel Ab Optiskt rent monohydrat av s-(-)-1-propyl-2',6'-pipekoloxylididhydroklorid, sett att framstella denna och farmaceutiska beredningar for lokalbedovning
GB8600398D0 (en) * 1986-01-08 1986-02-12 Glaxo Group Ltd Chemical compounds
GB8600397D0 (en) * 1986-01-08 1986-02-12 Glaxo Group Ltd Chemical compounds
GB8607824D0 (en) * 1986-03-27 1986-04-30 Glaxo Group Ltd Chemical compounds
DE3643957A1 (de) * 1986-12-22 1988-06-30 Bayer Ag Substituierte n-methylisoxazolidine
US4997841A (en) * 1987-08-13 1991-03-05 Glaxo Group Limited Indole derivatives
GB8719167D0 (en) * 1987-08-13 1987-09-23 Glaxo Group Ltd Chemical compounds
DE3730777A1 (de) * 1987-09-12 1989-03-23 Basf Ag Verfahren zur herstellung von imidazolidinonen und oxazolidinonen
US4965268A (en) * 1987-10-09 1990-10-23 E. I. Du Pont De Nemours And Company Aminomethyl oxooxazolidinyl cycloalkylbenzene derivatives useful as antibacterial agents
US4921869A (en) * 1987-10-09 1990-05-01 E. I. Du Pont De Nemours And Company Aminomethyl oxooxazolidinyl cycloalkylbenzene derivatives useful as antibacterial agents
US4801600A (en) * 1987-10-09 1989-01-31 E. I. Du Pont De Nemours And Company Aminomethyl oxooxazolidinyl cycloalkylbenzene derivatives useful as antibacterial agents
GB8724912D0 (en) * 1987-10-23 1987-11-25 Wellcome Found Indole derivatives
DE3823299A1 (de) * 1988-07-07 1990-01-11 Schering Ag Substituierte phenyl-pyrrolidin-2-one, -oxazolidin-2-one und -imidazolidin-2-one, ihre herstellung sowie verwendung in arzneimitteln
GB8819024D0 (en) * 1988-08-10 1988-09-14 Glaxo Group Ltd Chemical compounds
US5164510A (en) * 1988-09-15 1992-11-17 The Upjohn Company 5'Indolinyl-5β-amidomethyloxazolidin-2-ones
ATE112773T1 (de) * 1988-09-15 1994-10-15 Upjohn Co 5-indolinyl-5-beta-amidomethyloxazolidin-2-one, 3-(substituierte kondensierte)phenyl-5-beta amidomethyloxazolidin-2-one und 3-(nitrogen- substituierte)phenyl-5-beta-amidomethyloxazolid n-2-one.
DE3939238A1 (de) * 1989-11-28 1991-05-29 Bayer Ag Heterocyclisch substituierte acrylsaeureester
DE4013907A1 (de) * 1990-04-26 1991-10-31 Schering Ag Verfahren zur herstellung von gramin-derivaten
CZ283018B6 (cs) * 1991-02-01 1997-12-17 Merck Sharp And Dohme Limited Deriváty imidazolu, triazolu a tetrazolu a farmaceutické přípravky na jejich bázi
GB9104136D0 (en) * 1991-02-27 1991-04-17 Merck Sharp & Dohme Therapeutic agents
US5409941A (en) * 1992-02-03 1995-04-25 Pfizer Inc. 5-heteroyl indole derivatives

Also Published As

Publication number Publication date
DE19775091I2 (de) 2007-05-24
IE20010862A1 (en) 2003-03-05
CA2282890C (en) 2001-07-31
ATE204275T1 (de) 2001-09-15
IL98392A (en) 1996-01-19
RU2160736C2 (ru) 2000-12-20
HRP940524B1 (en) 1998-10-31
HU9200384D0 (en) 1992-06-29
NO1998005I1 (no) 1998-01-21
WO1991018897A1 (en) 1991-12-12
HK1000534A1 (en) 1998-04-03
LTIP419A (en) 1994-11-25
CZ288351B6 (en) 2001-05-16
IL114690A0 (en) 1995-11-27
NO920494D0 (no) 1992-02-06
EP0486666B1 (en) 1997-08-13
DE69127260T2 (de) 1997-12-04
ES2104708T3 (es) 1997-10-16
US5466699A (en) 1995-11-14
YU101091A (sh) 1994-04-05
MX9203421A (es) 1992-07-01
SK281621B6 (sk) 2001-05-10
CS172791A3 (en) 1992-02-19
DE69132691D1 (de) 2001-09-20
US5399574A (en) 1995-03-21
KR920702359A (ko) 1992-09-03
HU219974B (hu) 2001-10-28
JPH05502679A (ja) 1993-05-13
FI920503A0 (fi) 1992-02-06
ATE156823T1 (de) 1997-08-15
FI106262B (fi) 2000-12-29
EP0636623A1 (en) 1995-02-01
LV10274B (en) 1995-04-20
FI20001406A (fi) 2000-06-13
SI9111010A (en) 1997-12-31
NL980001I1 (nl) 1998-03-02
IL98392A0 (en) 1992-07-15
CA2282890A1 (en) 1991-12-08
HU211479A9 (en) 1995-11-28
YU48855B (sh) 2002-06-19
HRP940524A2 (en) 1996-06-30
DK0486666T3 (da) 1998-03-30
LV10274A (lv) 1994-10-20
MY110226A (en) 1998-03-31
CA2064815A1 (en) 1991-12-08
MC2210A1 (fr) 1992-11-26
NO920494L (no) 1992-03-30
US5863935A (en) 1999-01-26
GR3024828T3 (en) 1998-01-30
SA05260104A (ar) 2005-12-03
SI9111010B (sl) 2005-02-28
PT97888B (pt) 1998-12-31
JP2738461B2 (ja) 1998-04-08
EG19650A (en) 1995-09-30
EP0486666A1 (en) 1992-05-27
UA37178C2 (uk) 2001-05-15
HUT62289A (en) 1993-04-28
IL114690A (en) 1997-02-18
DE69127260D1 (de) 1997-09-18
FI105686B (fi) 2000-09-29
NZ238424A (en) 1993-12-23
SI21560B (sl) 2005-04-30
LT3264B (en) 1995-05-25
AU7957091A (en) 1991-12-31
AU646871B2 (en) 1994-03-10
FI960155A0 (fi) 1996-01-12
KR100215627B1 (ko) 1999-08-16
PL166214B1 (pl) 1995-04-28
EP0636623B1 (en) 2001-08-16
SI21560A (sl) 2005-02-28
SA05260104B1 (ar) 2006-04-04
NO300634B1 (no) 1997-06-30
IE911931A1 (en) 1991-12-18
NL980001I2 (nl) 1998-05-06
CA2064815C (en) 1999-11-16
DE69132691T2 (de) 2002-06-20
LU90205I2 (fr) 1998-04-06
FI960155A (fi) 1996-01-12

Similar Documents

Publication Publication Date Title
PT97888A (pt) Processo para a preparacao de compostos heterociclicos derivados de indol e de composicoes farmaceuticas que os contem
BR9509045A (pt) Derivado amino-heterocíclico processo para a preparação do mesmo composição farmacéutica e uso do derivado
PT90803A (pt) Processo para a preparacao de novos derivados de pirimidina
FI820281L (fi) Foerfarande foer framstaellning av 2-penemkompositioner med forfarandet framstaellda nya 2-penemkompositioner och dessa inehaollande farmaceutiska blandningar
ATE266398T1 (de) Pharmazeutische zusammensetzungen enthaltend tyrphostine
FR2677023B1 (fr) Derives de coumarine hydrosolubles, leur preparation et leur utilisation comme substrat d&#39;enzyme.
ES2016017A6 (es) Procedimiento para preparar derivados de acido 1,1-dioxocefem-4-carbotiolico.
ES8500742A1 (es) Procedimiento para la preparacion de derivados de acido fenilacetico
PT90815A (pt) Processo de preparacao de derivados da fenotiazina
ATE25968T1 (de) 1,1-diphenylpropanol-derivate, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzungen.
JPS55104266A (en) Novel pyridone derivative
JPS5759856A (en) Benzene derivative
ES8200891A1 (es) Procedimiento para preparar derivados del acido 2,7-fenan- trolina-9-carboxilico
YU128291A (sh) Postpak za dobijanje 6-(3-substituisanih aminopropionil) 7-deacetilforskolinskih derivata

Legal Events

Date Code Title Description
BB1A Laying open of patent application

Effective date: 19920325

FG3A Patent granted, date of granting

Effective date: 19980922

PC3A Transfer or assignment

Free format text: 19981111 ZENECA LIMITED GB

PC3A Transfer or assignment

Free format text: 20010131 ASTRAZENECA AB SE

MM4A Annulment/lapse due to non-payment of fees, searched and examined patent

Free format text: MAXIMUM VALIDITY LIMIT REACHED

Effective date: 20130922